Bramham K, Nelson-Piercy C. Autoimmune disease and the role of the obstetrician. Rheumatology in practice 2009; 7.2: 15

Rheumatology in practice

Reference list

Bramham K, Nelson-Piercy C. Autoimmune disease and the role of the obstetrician. Rheumatology in practice 2009; 7.2: 15–19.

References

1. Nelson Piercy C, Rosene-Montella K. Systemic lupus erythematosus. In Lee RV, Rosene-Montella K, Barbour LA, Garner PR, Keely E (eds). Medical Care of the Pregnant Patient (2nd edition). Philadelphia: American College of Physicians. 513–521.

2. Khamashta MA. Systemic lupus erythematosus and pregnancy. Best Pract Res Clin Rheumatol 2006; 20: 685–694.

3. D'Cruz, DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369: 587–596.

4. Gordon P, Beedham T, Khamashta M, D'Cruz D. Systemic lupus erythematosus in pregnancy. The Obstetrician and Gynaecologist 2004; 6: 80–87.

5. Hayslett JP. The effect of systemic lupus erythematosus on pregnancy and pregnancy outcome. Am J Reprod Immunol 1992; 28: 199–204.

6. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52: 514–521.

7. Østensen M, Khamashta M, Lockshin M et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006. 8: 209.

8. Friedman JM. ACE inhibitors and congenital anomalies. N Engl J Med 2006; 354: 2498–2500.

9. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; CD004659.

10. Johnson SR, Gladman DD, Urowitz MB, Ibañez D, Granton JT. Pulmonary hypertension in systemic lupus. Lupus 2004; 13: 506–509.

11. Chakravarty EF, Colón I, Langen ES et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol, 2005. 192: 1897–1904.

12. Cervera R, Font J, Carmona F, Balasch J. Pregnancy outcome in systemic lupus erythematosus: good news for the new millennium. Autoimmun Rev 2002; 1: 354–359.

13. Cortés-Hernández J, Ordi-Ros J, Paredes F et al. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 2002; 41: 643–650.

14. Ruiz-Irastorza G, Lima F, Alves J et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996. 35: 133–188.

15. Benediktsson R, Calder AA, Edwards CR, Seckl JR. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf) 1997; 46: 161–166.

16. Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385–392.

17. Carmichael SL, Shaw GM, MA C et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197: 585 e1–7; discussion 683–684 e1–7.

18. Källén B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac J 2003; 40: 624–628.

19. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997; 56: 335–40.

20. Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol 2003; 16: 161–167.

21. Direskeneli H, Buchanan NM, Khamashta MA et al. Markers of vascular damage in lupus pregnancy. Clin Exp Rheumatol 1997; 15: 535–539.

22. Sibai BM, Lindheimer M, Hauth J et al. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 339: 667–671.

23. Chappell LC, Enye S, Seed P et al. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension 2008 51: 1002–1009.

24. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 899–907.

25. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV.

26. Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus 2006; 15: 148–155.

27. Soubassi L, Haidopoulos D, Sindos M et al. Pregnancy outcome in women with pre-existing lupus nephritis. J Obstet Gynaecol 2004; 24: 630–634.

28. Oviasu E, Hicks J, Cameron JS. The outcome of pregnancy in women with lupus nephritis. Lupus 1991; 1: 19–25.

29. Hou S. Pregnancy in chronic renal insufficiency and end-stage renal disease. Am J Kidney Dis 1999; 33: 235–252.

30. Williams D, Davison J. Chronic kidney disease in pregnancy. BMJ 2008; 336: 211–215.

31. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost, 2006; 4: 295–306.

32. Nelson-Piercy C. Handbook of Obstetric Medicine. London: Informa, 2006. 155–156.

33. Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003; 142: 678–683.

34. Friedman DM, Rupel A, Buyon JP. Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. Curr Rheumatol Rep 2007; 9: 101–108.

35. Derksen RH, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50: 1028–1039.

36. Birdsall M, Pattison N, Chamley L. Antiphospholipid antibodies in pregnancy. Aust N Z J Obstet Gynaecol 1992; 32: 328–330.

37. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253–257.

38. Silver RK, MacGregor SN, Sholl JS et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993; 169: 1411–1417.

39. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995; 86: 555–559.

40. Lima F, Khamashta MA, Buchanan NM et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol, 1996. 14: 131–136.

41.Lynch A, Silver R, Emlen W. Antiphospholipid antibodies in healthy pregnant women. Rheum Dis Clin North Am 1997; 23: 55–70.

42. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am J Obstet Gynecol 1997; 176: 1099–1100.

43. Ramsey-Goldman R, Kutzer JE, Kuller LH et al. Previous pregnancy outcome is an important determinant of subsequent pregnancy outcome in women with systemic lupus erythematosus. Am J Reprod Immunol 1992; 28: 195–198.

44. Martínez-Rueda JO, Arce-Salinas CA, Kraus A, Alcocer-Varela J, Alarcón-Segovia D. Factors associated with fetal losses in severe systemic lupus erythematosus. Lupus 1996; 52: 113–119.

45. Out HJ, Bruinse HW, Christiaens GC et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992; 167: 26–32.

46. Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160: 439–443.

47. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 2003; 101: 1333–1344.

48. Østensen M, Förger F, Nelson JL et al. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheum Dis, 2005; 64: 839–844.

49. Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997; 23: 195–212.

50. Drossaers-Bakker KW, Zwinderman AH, van Zeben D, Breedveld FC, Hazes JM. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis 2002; 61: 405–408.

51. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf, 2004; 27: 307–324.

52. Roux CH, Brocq O, Breuil V et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46: 695–698.

53. Steen VD. Pregnancy in scleroderma. Rheum Dis Clin North Am 2007; 33: 345–358, vii.

54. Giordano M, Valentini G, Lupoli S, Giordano A. Pregnancy and systemic sclerosis. Arthritis Rheum 1985; 28: 237–238.

55. Steen VD, Conte C, Day N et al. Pregnancy in women with systemic sclerosis. Arthritis Rheum 1989; 32: 151–157.

56. Elliot CA, Stewart P, Webster VJ et al. The use of iloprost in early pregnancy in patients with pulmonary arterial hypertension. Eur Respir J 2005; 26: 168–173.

57. Haga HJ, Gjesdal CG, Koksvik HS et al. Pregnancy outcome in patients with primary Sjogren's syndrome. a case-control study. J Rheumatol 2005; 32: 1734–1736.

Published by Hayward Medical Communications